Coherence Neuro's Implant Listened to Three Tumors in the Operating Room

In a surgical theater at Melbourne’s Royal Melbourne Hospital, a thin, flexible film of electrodes was placed on the exposed brain of a patient undergoing tumor removal. For about thirty minutes, the device, called CIPHER, listened to the electrical activity of the tissue. This was not an experiment in motor control or communication, but a first, tentative step toward a new kind of cancer management: using a brain-computer interface to read the bioelectric signature of a tumor itself [Jake Stroud - Coherence Neuro | LinkedIn].

For Coherence Neuro, a San Francisco startup founded in 2022, this brief intraoperative procedure represents the initial clinical validation of a much larger ambition. The company is developing SOMA, a fully implantable system designed to be left in the brain after tumor-resection surgery. Its goal is to continuously monitor the electrical microenvironment of a glioma and deliver targeted stimulation, aiming to overwrite the signals that may drive cancer progression [coherenceneuro.com/product]. It is a closed-loop therapeutic approach, applying the principles of neuromodulation to one of neurology’s most intractable problems.

The Bioelectric Wedge in Oncology

Most brain-computer interface (BCI) ventures focus on restoring function, whether for paralysis or sensory loss. Coherence Neuro’s wedge is different. It treats the brain not as an organ to be repaired, but as a circuit where disease manifests electrically. The company’s thesis, rooted in co-founder Elise Jenkins’s PhD research at Cambridge on electrotherapy for brain tumors, posits that cancers create a distinct bioelectric footprint [Department of Engineering]. By sensing that activity in real time, an implant could provide clinicians with a continuous stream of data far more frequent than the MRI scans spaced months apart that define current monitoring. More ambitiously, the device could then deliver precise electrical stimulation to disrupt the tumor’s own signaling, a concept the company describes as guiding the body toward health [Tech Funding News, November 2025].

This two-pronged approach is reflected in the company’s two core technologies. CIPHER is the flexible, high-density cortical probe used for temporary recording and stimulation during surgery. Data from these acute procedures is meant to inform the design of SOMA, the chronic, fully implantable therapeutic system intended for long-term use [PERPLEXITY SONAR PRO BRIEF].

A Consortium and a $10 Million Vote of Confidence

Progress toward that chronic implant is being supported by a recent €11.5 million SPARCLE Consortium in Europe, which includes neurotechnology companies and research organizations, and a $10 million seed round closed in November 2025 [PERPLEXITY SONAR PRO BRIEF]. The financing was led by Topology Ventures and Artesian, with a notable list of participants including Blackbird, Possible Ventures, and the OpenAI Startup Fund. Perhaps most telling for a hardware-heavy, clinically rigorous endeavor is the participation of Founders Fund, an investor known for backing foundational technology bets [Tech Funding News, November 2025].

The capital is fueling a hiring spree across engineering and clinical operations. Open roles point to the complex path ahead: the company is recruiting for a Senior Clinical Scientist in Cambridge to manage first-in-human trials, a Surgical Development and Human Factors Lead in San Francisco, and multiple hardware engineers [Ramp Jobs]. This bifurcated team structure, spanning the Bay Area and a Cambridge outpost, underscores the blend of Silicon Valley engineering and deep clinical neuroscience required to move forward.

The Long Road Through Regulated Territory

The ambition is profound, but the pathway is one of the most demanding in medicine. Coherence Neuro is not building a wellness device; it is aiming to create an active, implantable therapeutic for a lethal cancer. Every claim about sensing disease progression or delivering therapeutic stimulation must eventually be proven in randomized controlled trials under FDA or EMA scrutiny, a process measured in years and hundreds of millions of dollars. The company’s initial work with CIPHER is wisely framed as a feasibility study to gather data, not a therapeutic intervention [BrainPatch® Blog].

The technical and biological unknowns are significant. The relationship between specific bioelectric patterns and tumor behavior is an emerging science. Designing a stimulator that can safely and effectively modulate this environment for years, with an MRI-compatible device that charges wirelessly, is a monumental engineering challenge [The World of Implantable Devices, 2026-01-17]. Furthermore, the commercial landscape for implantable BCIs is becoming crowded, though with different targets. While no direct competitors were named in sources, companies like Synchron and Precision Neuroscience are advancing the regulatory and surgical playbooks for chronic brain implants, albeit for different indications. Coherence Neuro’s success hinges on proving its unique oncology application is not just scientifically plausible, but clinically necessary.

The Patient at the Center of the Bet

The disease in Coherence Neuro’s sights is glioma, and its most aggressive form, glioblastoma. This patient population faces a stark reality. The standard of care today involves maximal safe surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, prognosis remains poor, and monitoring for recurrence relies on intermittent MRI scans that provide a snapshot in time, often revealing progression only after it is well established. For these patients and their clinicians, a device that could offer a real-time window into the tumor microenvironment,and potentially intervene,would represent a fundamental shift from reactive to proactive management.

The three patients at Royal Melbourne Hospital were the first to have their tumors listened to by Coherence Neuro’s technology. The long-term hope is that future patients might live with a device that does not just listen, but also speaks back to the disease [WIRED Middle East].

Sources

1. [Tech Funding News, November 2025] Startup in spotlight: Coherence Neuro raises $10M to launch closed-loop neuro system for cancer treatment | https://techfundingnews.com/startup-in-spotlight-coherence-neuro-raises-10m-to-launch-closed-loop-neuro-dystem-for-cancer-treatment/
2. [Jake Stroud - Coherence Neuro | LinkedIn] LinkedIn post on temporary implant procedure
3. [coherenceneuro.com/product] Coherence Neuro product page for SOMA
4. [Department of Engineering] Description of Elise Jenkins's PhD research at Cambridge
5. [PERPLEXITY SONAR PRO BRIEF] Summary of company technology and SPARCLE Consortium
6. [Ramp Jobs] Coherence Neuro careers page listing open roles
7. [BrainPatch® Blog] Description of CIPHER's initial trial use
8. [The World of Implantable Devices, 2026-01-17] Article on SOMA-1 device specifications
9. [WIRED Middle East] Article on Coherence Neuro's BCI for tumor management